ID   PLAT5_RAT               Reviewed;         287 AA.
AC   Q4KLN5;
DT   17-JUN-2020, integrated into UniProtKB/Swiss-Prot.
DT   02-AUG-2005, sequence version 1.
DT   24-JUL-2024, entry version 115.
DE   RecName: Full=Phospholipase A and acyltransferase 5 {ECO:0000305};
DE   AltName: Full=Ca(2+)-independent N-acyltransferase;
DE            Short=iNAT;
DE            EC=2.3.1.- {ECO:0000269|PubMed:17158102};
DE            EC=3.1.1.32 {ECO:0000250|UniProtKB:Q9CPX5};
DE            EC=3.1.1.4 {ECO:0000250|UniProtKB:Q9CPX5};
DE   AltName: Full=H-rev107-like protein 5;
DE   AltName: Full=HRAS-like suppressor 5;
DE            Short=HRSL5;
DE   AltName: Full=Rat LRAT-like protein-1 {ECO:0000303|PubMed:17158102};
DE            Short=RLP-1 {ECO:0000303|PubMed:17158102};
GN   Name=Plaat5 {ECO:0000312|RGD:1308376};
GN   Synonyms=Hrasls5 {ECO:0000312|EMBL:AAH99084.1, ECO:0000312|RGD:1308376},
GN   Hrlp5, Rlp-1 {ECO:0000303|PubMed:17158102};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116 {ECO:0000312|EMBL:AAH99084.1};
RN   [1] {ECO:0000312|EMBL:BAF41148.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
RP   CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17158102; DOI=10.1074/jbc.m606369200;
RA   Jin X.H., Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N.;
RT   "Discovery and characterization of a Ca2+-independent
RT   phosphatidylethanolamine N-acyltransferase generating the anandamide
RT   precursor and its congeners.";
RL   J. Biol. Chem. 282:3614-3623(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [3] {ECO:0000312|EMBL:AAH99084.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis {ECO:0000312|EMBL:AAH99084.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Exhibits both phospholipase A1/2 and acyltransferase
CC       activities (By similarity). Shows phospholipase A1 (PLA1) and A2 (PLA2)
CC       activity, catalyzing the calcium-independent release of fatty acids
CC       from the sn-1 or sn-2 position of glycerophospholipids (By similarity).
CC       Shows N-acyltransferase activity, catalyzing the calcium-independent
CC       transfer of a fatty acyl group at the sn-1 position of
CC       phosphatidylcholine (PC) and other glycerophospholipids to the primary
CC       amine of phosphatidylethanolamine (PE), forming N-
CC       acylphosphatidylethanolamine (NAPE), which serves as precursor for N-
CC       acylethanolamines (NAEs) (PubMed:17158102).
CC       {ECO:0000250|UniProtKB:Q96KN8, ECO:0000250|UniProtKB:Q9CPX5,
CC       ECO:0000269|PubMed:17158102}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC         Evidence={ECO:0000250|UniProtKB:Q9CPX5};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 2-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:18689,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:57875; EC=3.1.1.32;
CC         Evidence={ECO:0000250|UniProtKB:Q9CPX5};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1-
CC         hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-
CC         phosphocholine = 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) +
CC         N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-1,2-di-(9Z-octadecenoyl)-sn-
CC         glycero-3-phosphoethanolamine; Xref=Rhea:RHEA:45476,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:73003,
CC         ChEBI:CHEBI:74986, ChEBI:CHEBI:85277;
CC         Evidence={ECO:0000269|PubMed:17158102};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45477;
CC         Evidence={ECO:0000305|PubMed:17158102};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         1,2-dihexadecanoyl-sn-glycero-3-phosphocholine = 1-hexadecanoyl-sn-
CC         glycero-3-phosphocholine + H(+) + N-hexadecanoyl-1,2-di-(9Z-
CC         octadecenoyl)-sn-glycero-3-phosphoethanolamine; Xref=Rhea:RHEA:45176,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:72999,
CC         ChEBI:CHEBI:74986, ChEBI:CHEBI:78097;
CC         Evidence={ECO:0000269|PubMed:17158102};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45177;
CC         Evidence={ECO:0000305|PubMed:17158102};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         1,2-dihexadecanoyl-sn-glycero-3-phosphocholine = 2-hexadecanoyl-sn-
CC         glycero-3-phosphocholine + H(+) + N-hexadecanoyl-1,2-di-(9Z-
CC         octadecenoyl)-sn-glycero-3-phosphoethanolamine; Xref=Rhea:RHEA:45172,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72999, ChEBI:CHEBI:74986,
CC         ChEBI:CHEBI:76078, ChEBI:CHEBI:78097;
CC         Evidence={ECO:0000269|PubMed:17158102};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45173;
CC         Evidence={ECO:0000305|PubMed:17158102};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + a 1,2-diacyl-sn-
CC         glycero-3-phosphoethanolamine = a 1-acyl-sn-glycero-3-phosphocholine
CC         + H(+) + N-acyl-1,2-diacyl-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:45192, ChEBI:CHEBI:15378, ChEBI:CHEBI:57643,
CC         ChEBI:CHEBI:58168, ChEBI:CHEBI:62537, ChEBI:CHEBI:64612;
CC         Evidence={ECO:0000250|UniProtKB:Q9CPX5};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45193;
CC         Evidence={ECO:0000250|UniProtKB:Q9CPX5};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + a 1,2-diacyl-sn-
CC         glycero-3-phosphoethanolamine = a 2-acyl-sn-glycero-3-phosphocholine
CC         + H(+) + N-acyl-1,2-diacyl-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:45188, ChEBI:CHEBI:15378, ChEBI:CHEBI:57643,
CC         ChEBI:CHEBI:57875, ChEBI:CHEBI:62537, ChEBI:CHEBI:64612;
CC         Evidence={ECO:0000250|UniProtKB:Q9CPX5};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45189;
CC         Evidence={ECO:0000250|UniProtKB:Q9CPX5};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1-
CC         hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine = 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + N,1,2-tri-(9Z-
CC         octadecenoyl)-sn-glycero-3-phosphoethanolamine; Xref=Rhea:RHEA:56504,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:73001,
CC         ChEBI:CHEBI:74986, ChEBI:CHEBI:85291;
CC         Evidence={ECO:0000269|PubMed:17158102};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56505;
CC         Evidence={ECO:0000305|PubMed:17158102};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 9.0. {ECO:0000269|PubMed:17158102};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:17158102}.
CC   -!- TISSUE SPECIFICITY: Expressed in testis. {ECO:0000269|PubMed:17158102}.
CC   -!- SIMILARITY: Belongs to the H-rev107 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB255646; BAF41148.1; -; mRNA.
DR   EMBL; AABR07006120; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC099084; AAH99084.1; -; mRNA.
DR   RefSeq; NP_001034096.1; NM_001039007.1.
DR   AlphaFoldDB; Q4KLN5; -.
DR   SMR; Q4KLN5; -.
DR   STRING; 10116.ENSRNOP00000037070; -.
DR   SwissLipids; SLP:000001909; -.
DR   PaxDb; 10116-ENSRNOP00000037070; -.
DR   Ensembl; ENSRNOT00055040270; ENSRNOP00055032709; ENSRNOG00055023430.
DR   Ensembl; ENSRNOT00060057257; ENSRNOP00060047335; ENSRNOG00060033000.
DR   Ensembl; ENSRNOT00065055459; ENSRNOP00065045627; ENSRNOG00065032213.
DR   GeneID; 293711; -.
DR   KEGG; rno:293711; -.
DR   UCSC; RGD:1308376; rat.
DR   AGR; RGD:1308376; -.
DR   CTD; 117245; -.
DR   RGD; 1308376; Plaat5.
DR   VEuPathDB; HostDB:ENSRNOG00000023528; -.
DR   eggNOG; ENOG502S0JN; Eukaryota.
DR   HOGENOM; CLU_070482_0_0_1; -.
DR   InParanoid; Q4KLN5; -.
DR   OrthoDB; 3059772at2759; -.
DR   PhylomeDB; Q4KLN5; -.
DR   TreeFam; TF330836; -.
DR   Reactome; R-RNO-1482839; Acyl chain remodelling of PE.
DR   PRO; PR:Q4KLN5; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000023528; Expressed in testis and 12 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0052740; F:1-acyl-2-lysophosphatidylserine acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016410; F:N-acyltransferase activity; IDA:MGI.
DR   GO; GO:0052739; F:phosphatidylserine 1-acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008970; F:phospholipase A1 activity; ISO:RGD.
DR   GO; GO:0004623; F:phospholipase A2 activity; ISO:RGD.
DR   GO; GO:0070292; P:N-acylphosphatidylethanolamine metabolic process; IDA:MGI.
DR   Gene3D; 3.90.1720.10; endopeptidase domain like (from Nostoc punctiforme); 1.
DR   InterPro; IPR051496; H-rev107_PLA/AT.
DR   InterPro; IPR007053; LRAT_dom.
DR   PANTHER; PTHR13943; HRAS-LIKE SUPPRESSOR - RELATED; 1.
DR   PANTHER; PTHR13943:SF2; PHOSPHOLIPASE A AND ACYLTRANSFERASE 5; 1.
DR   Pfam; PF04970; LRAT; 1.
DR   PROSITE; PS51934; LRAT; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Cytoplasm; Hydrolase; Lipid metabolism;
KW   Reference proteome; Transferase.
FT   CHAIN           1..287
FT                   /note="Phospholipase A and acyltransferase 5"
FT                   /id="PRO_0000450339"
FT   DOMAIN          144..257
FT                   /note="LRAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283"
FT   REGION          48..72
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          86..138
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        49..72
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        120..137
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        154
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283"
FT   ACT_SITE        166
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283"
FT   ACT_SITE        241
FT                   /note="Acyl-thioester intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01283"
SQ   SEQUENCE   287 AA;  31749 MW;  1F9FA50E46163148 CRC64;
     MIPGHRGPWS APLCRRLVPA GHSGMGLSPA ASGEYGIRLF RVPWPSRPKQ ISRTASTESS
     DTQPTNDSAS SQALVVQFLP KLPKQDRGLE QARSLRQGQK PEINLELIPS KKRTEMIPSS
     DSEIEGNLKN QAAESNQKPR PGDLIEIFRI GYEHWAIYVE DDCVVHLAPP SEFEAGSITS
     IFSNRAVVKY SRLQDVLHGC SWKINNKLDG TYLPLPVDKI IQRTKNMINK IVQYSLIEGN
     CEHFVNDLRY GVPRSQQVEH VLVEGAKAAG AVLSAVVDSI RPKPITA
//
